Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Dermoscopic Clues for Diagnosing Amelanotic Melanoma and Its Mimics

Description

The talk reviews dermoscopic clues for diagnosing amelanotic and lightly pigmented melanoma and distinguishing it from common mimics. The speaker emphasizes that even lesions resembling basal cell carcinoma, dermatofibroma, inflammatory conditions, or squamous cell carcinoma should be biopsied when features are atypical. For melanoma, helpful clues include light brown featureless areas, milky pink/red zones, globally disorganized patterns, blurry or less crisply focused vessels, peripheral globules, and ulceration when disease is more advanced. In contrast, basal cell carcinoma more often shows arborizing vessels, characteristic pigmented structures, and can ulcerate even when very small; below the knee, vascular clues may be absent. Squamous cell carcinoma may mimic melanoma through medium-brown pigmentation, brown dots/lines, and keratin pearls. Dermatofibroma is suggested by a central scar-like area with a relatively organized, lace-like periphery, whereas melanoma shows broader color variation and disorganization. The lecture also highlights that some amelanotic melanomas can be mistaken for inflammation, making nonresponse to treatment an important clue. A major focus is facial lentigo maligna, where diagnosis is challenging because of overlap with pigmented actinic keratosis and lichen planus–like keratosis. On the face, the speaker recommends an inverse checklist approach: if features of AK or LPLK are not convincing, biopsy to exclude melanoma in situ. Newer dermoscopic concepts such as perifollicular linear projections, rhomboidal structures, and follicular changes improve recognition of lentigo maligna.

View more

Conclusions

  • Amelanotic and lightly pigmented melanoma can closely mimic basal cell carcinoma, squamous cell carcinoma, dermatofibroma, and inflammatory dermatoses, so a low threshold for biopsy is warranted when the pattern is not classic.
  • For melanoma, especially subtle lesions, light brown featureless areas, milky pink/red areas, disorganization, and blurry or polymorphous vessels are key clues.
  • Basal cell carcinoma is favored by crisp arborizing vessels, characteristic pigmented structures, and a tendency to ulcerate even when very small.
  • Squamous cell carcinoma with pigment can mimic melanoma, but medium brown pigmentation, keratinization, and keratin pearls support SCC.
  • Dermatofibroma is usually more organized, with a central scar-like area and a relatively symmetric or lace-like peripheral pattern, whereas melanoma tends to be more globally disorganized.
  • Melanomas that look inflammatory or nonspecific are often initially misread, so unilateral, nonresponsive, minimally scaly, depigmented lesions should prompt reconsideration and biopsy.
  • Lentigo maligna on the face has special follicular patterns, and perifollicular linear projections are an important newer diagnostic clue.
  • An inverse diagnostic approach for facial lesions—first excluding actinic keratosis, lichen planus-like keratosis, seborrheic keratosis, and similar benign patterns—can improve recognition of lentigo maligna.
  • Because facial lentigo maligna overlaps clinically and dermoscopically with AK, SK, and other benign facial lesions, checklist-based assessment is helpful but not perfect.
  • Overall, the presentation emphasizes that careful pattern recognition, comparison with mimics, and biopsy of suspicious outliers are essential to avoid missing melanoma and lentigo maligna.
  • JAAD 2012 Apr;66(4):589-97. PMID 21839538.
  • Zalaudek et al. Arch Dermatol. 2008;144(10):1375-9.
  • Schiffner et al. J Am Acad Dermatol. 2000.
  • Perifollicular linear projections: A dermatoscopic criterion for the diagnosis of lentigo maligna on the face.#10.1016/j.jaad.2023.07.1036
  • International Dermoscopy Society consensus recommendations for the management of lentigo maligna.
  • JEADV 2026 Mar 19.